Fundraising Fox

Clearside Biomedical

Alpharetta, US · Founded 2011 · Delaware corporation · 22 employees on LinkedIn · 5 known investors

Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.

BiotechHealthtechMedical Devices

Founders & leadership

Clearside Biomedical was founded in 2011 by Mark Prausnitz.

MP
Mark PrausnitzinCo-FounderDirector at Piezo Therapeutics
CD
Charles DeignanExecutive
GNGlenn Noronha
Glenn NoronhainChief Scientific Officer; Head of Development2013–2018
DH
Daniel H. WhiteinFounder and former CEO2011–2019

Board

EZ
Evgeny ZaytsevBoard director
DYDerek Yoon
Derek YooninBoard directorPresident & CEO at Solasta Ventures
CL
Christy L. Shaffer, Ph.D.Board director
CBClay B. Thorp
Clay B. ThorpinBoard directorGeneral Partner at Hatteras Venture Partners
CS
Christy ShafferBoard director
WH
William HumphriesBoard director
GC
Gerald Cagle, Ph.D.Board director
RC
Richard CroarkinBoard director

Investors · 5

HEALTHCARE ROYALTY PARTNERSNew York
Mountain Group CapitalNashville
Solasta VenturesBoston
HatterasreportedRaleigh
Hatteras Venture Partnersreported · 2 sourcesResearch Triangle · $500K – $4Mvia Clay Thorp · board

Reported raises · per SEC filings

Form D private placements

$40.6M disclosed across 6 rounds · 2012–2019

▶$3.3MraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George LasezkayExecutive Officer, Director
  • Charles A. DeignanExecutive Officer
  • William D. HumphriesDirector
  • Clay B. ThorpDirector
  • Jeffrey L. EdwardsDirector
  • Christy ShafferDirector
  • Richard CroarkinDirector
Offering amount
$3.3M
Amount sold
$3.3M
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$320KraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William D. HumphriesDirector
  • Gerald Cagle, Ph.D.Director
  • Evgeny ZaytsevDirector
  • Derek YoonDirector
  • Christy L. Shaffer, Ph.D.Director
  • Charles DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Clay B. ThorpDirector
  • Daniel H. WhiteExecutive Officer, Director
  • Richard CroarkinDirector
Offering amount
$320K
Amount sold
$320K
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.4MraisedDec 2015 · 9 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charlie DeignanExecutive Officer
  • Clay ThorpDirector
  • William HumphriesDirector
  • Evgeny ZaytsevDirector
  • Christy ShafferDirector
  • Daniel WhiteExecutive Officer, Director, Promoter
  • Gerald D. CagleDirector
Offering amount
$20M
Amount sold
$14.4M
First sale
Nov 2015
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.2MraisedSep 2014 · 31 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector, Promoter
  • Clay ThorpDirector
  • Daniel H. WhiteExecutive Officer, Director, Promoter
  • Charles A. DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Evgeny ZaytsevDirector
  • William HumphriesDirector
  • Mark PrausnitzDirector, Promoter
  • Gerald D. CagleDirector
Offering amount
$20M
Amount sold
$16.2M
Minimum investment
$50K
Finders' fees
$118K
Proceeds to insiders
$550K
First sale
Aug 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMay 2014 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William HumphriesDirector
  • Jerry CagleDirector
  • Clay ThorpDirector
  • Mark PrausnitzDirector
  • Charles A. DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Daniel H. WhiteExecutive Officer, Director
  • Christy ShafferDirector
Offering amount
$6M
Amount sold
$3M
Proceeds to insiders
$450K
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedFeb 2012 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector
  • Clay ThorpDirector
  • Daniel H. WhiteExecutive Officer
  • Mark PrausnitzDirector
Offering amount
$4M
Amount sold
$3.2M
Minimum investment
$37.5K
Proceeds to insiders
$500K
First sale
Jan 2012
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha12 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits12 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Public11 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall St10 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.

Companies competing with Clearside Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Clearside Biomedical: Debt-Free Biotech Bankruptcy Sparks Equity Holder Fightelevenflo.com · Mar 2026Clearside Biomedical receives court approval for asset sale bidding procedures By Investing.cominvesting.com · Dec 2025Clearside Biomedical's Financial Performance in the Biopharmaceutical Industrycbonds.com · Nov 2025Clearside Biomedical amends royalty agreement, receives $3 million payment By Investing.cominvesting.com · Sep 2025Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - BioSpacebiospace.com · Mar 2025

Frequently asked questions

What does Clearside Biomedical do?
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.
Who founded Clearside Biomedical?
Clearside Biomedical was founded by Mark Prausnitz in 2011.
Who are Clearside Biomedical's investors?
Clearside Biomedical's investors include HEALTHCARE ROYALTY PARTNERS, Mountain Group Capital, Solasta Ventures, Hatteras, Hatteras Venture Partners.
How much funding has Clearside Biomedical raised?
Clearside Biomedical has disclosed $40.6M raised across 6 rounds.
Where is Clearside Biomedical headquartered?
Clearside Biomedical is headquartered in Alpharetta, US.